-
Something wrong with this record ?
Rhus coriaria L. (Sumac) Demonstrates Oncostatic Activity in the Therapeutic and Preventive Model of Breast Carcinoma
P. Kubatka, M. Kello, K. Kajo, M. Samec, A. Liskova, K. Jasek, L. Koklesova, T. Kuruc, M. Adamkov, K. Smejkal, E. Svajdlenka, P. Solar, M. Pec, D. Büsselberg, V. Sadlonova, J. Mojzis
Language English Country Switzerland
Document type Journal Article
Grant support
VEGA 1/0136/19; VEGA 1/0653/19; and 1/0753/17
Scientific Grant Agency of the Ministry of Education of the Slovak Republic
APVV-16-0021 and APVV-16-0446
Slovak Research and Development Agency
ITMS2014+: 313011V455
Open scientific community for modern interdisciplinary research in medicine (OPENMED)
NPRP 11S-1214-170101
National Priorities Research Program grant (NPRP 11S-1214-170101; awarded to Professor Dr. Dietrich Büsselberg, June 2019-Current) from the Qatar National Research Fund (QNRF, a member of Qatar Foundation).
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
33375383
DOI
10.3390/ijms22010183
Knihovny.cz E-resources
- MeSH
- Apoptosis MeSH
- Cell Cycle MeSH
- Antineoplastic Agents, Phytogenic pharmacology MeSH
- Humans MeSH
- MicroRNAs genetics MeSH
- Mice, Inbred BALB C MeSH
- Mice, Nude MeSH
- Mice MeSH
- Biomarkers, Tumor genetics metabolism MeSH
- Tumor Cells, Cultured MeSH
- Breast Neoplasms drug therapy metabolism pathology MeSH
- Rats, Sprague-Dawley MeSH
- Cell Proliferation MeSH
- Gene Expression Regulation, Neoplastic drug effects MeSH
- Rhus chemistry MeSH
- Plant Extracts pharmacology MeSH
- Xenograft Model Antitumor Assays MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Comprehensive scientific data provide evidence that isolated phytochemicals or whole plant foods may beneficially modify carcinogenesis. The aim of this study was to evaluate the oncostatic activities of Rhus coriaria L. (sumac) using animal models (rat and mouse), and cell lines of breast carcinoma. R. coriaria (as a powder) was administered through the diet at two concentrations (low dose: 0.1% (w/w) and high dose: 1 % (w/w)) for the duration of the experiment in a syngeneic 4T1 mouse and chemically-induced rat mammary carcinoma models. After autopsy, histopathological and molecular analyses of tumor samples in rodents were performed. Moreover, in vitro analyses using MCF-7 and MDA-MB-231 cells were conducted. The dominant metabolites present in tested R. coriaria methanolic extract were glycosides of gallic acid (possible gallotannins). In the mouse model, R. coriaria at a higher dose (1%) significantly decreased tumor volume by 27% when compared to controls. In addition, treated tumors showed significant dose-dependent decrease in mitotic activity index by 36.5% and 51% in comparison with the control group. In the chemoprevention study using rats, R. coriaria at a higher dose significantly reduced the tumor incidence by 20% and in lower dose non-significantly reduced tumor frequency by 29% when compared to controls. Evaluations of the mechanism of oncostatic action using valid clinical markers demonstrated several positive alterations in rat tumor cells after the treatment with R. coriaria. In this regard, histopathological analysis of treated tumor specimens showed robust dose-dependent decrease in the ratio of high-/low-grade carcinomas by 66% and 73% compared to controls. In treated rat carcinomas, we found significant caspase-3, Bax, and Bax/Bcl-2 expression increases; on the other side, a significant down-regulation of Bcl-2, Ki67, CD24, ALDH1, and EpCam expressions and MDA levels. When compared to control specimens, evaluation of epigenetic alterations in rat tumor cells in vivo showed significant dose-dependent decrease in lysine methylation status of H3K4m3 and H3K9m3 and dose-dependent increase in lysine acetylation in H4K16ac levels (H4K20m3 was not changed) in treated groups. However, only in lower dose of sumac were significant decreases in the expression of oncogenic miR210 and increase of tumor-suppressive miR145 (miR21, miR22, and miR155 were not changed) observed. Finally, only in lower sumac dose, significant decreases in methylation status of three out of five gene promoters-ATM, PTEN, and TIMP3 (PITX2 and RASSF1 promoters were not changed). In vitro evaluations using methanolic extract of R. coriaria showed significant anticancer efficacy in MCF-7 and MDA-MB-231 cells (using Resazurin, cell cycle, annexin V/PI, caspase-3/7, Bcl-2, PARP, and mitochondrial membrane potential analyses). In conclusion, sumac demonstrated significant oncostatic activities in rodent models of breast carcinoma that were validated by mechanistic studies in vivo and in vitro.
Biomedical Research Center Slovak Academy of Sciences 845 05 Bratislava Slovakia
Department of Medical Biology Faculty of Medicine P J Šafárik University 040 11 Kosice Slovakia
Department of Natural Drugs Faculty of Pharmacy Masaryk University 612 42 Brno Czech Republic
Department of Pathology St Elisabeth Oncology Institute 812 50 Bratislava Slovakia
Department of Pharmacology Faculty of Medicine P J Šafárik University 040 11 Košice Slovakia
Weill Cornell Medicine in Qatar Qatar Foundation Education City 24144 Doha Qatar
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026325
- 003
- CZ-PrNML
- 005
- 20211026133004.0
- 007
- ta
- 008
- 211013s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms22010183 $2 doi
- 035 __
- $a (PubMed)33375383
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kubatka, Peter $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia $u Division of Oncology, Biomedical Center Martin, Comenius University in Bratislava, Jessenius Faculty of Medicine, 036 01 Martin, Slovakia
- 245 10
- $a Rhus coriaria L. (Sumac) Demonstrates Oncostatic Activity in the Therapeutic and Preventive Model of Breast Carcinoma / $c P. Kubatka, M. Kello, K. Kajo, M. Samec, A. Liskova, K. Jasek, L. Koklesova, T. Kuruc, M. Adamkov, K. Smejkal, E. Svajdlenka, P. Solar, M. Pec, D. Büsselberg, V. Sadlonova, J. Mojzis
- 520 9_
- $a Comprehensive scientific data provide evidence that isolated phytochemicals or whole plant foods may beneficially modify carcinogenesis. The aim of this study was to evaluate the oncostatic activities of Rhus coriaria L. (sumac) using animal models (rat and mouse), and cell lines of breast carcinoma. R. coriaria (as a powder) was administered through the diet at two concentrations (low dose: 0.1% (w/w) and high dose: 1 % (w/w)) for the duration of the experiment in a syngeneic 4T1 mouse and chemically-induced rat mammary carcinoma models. After autopsy, histopathological and molecular analyses of tumor samples in rodents were performed. Moreover, in vitro analyses using MCF-7 and MDA-MB-231 cells were conducted. The dominant metabolites present in tested R. coriaria methanolic extract were glycosides of gallic acid (possible gallotannins). In the mouse model, R. coriaria at a higher dose (1%) significantly decreased tumor volume by 27% when compared to controls. In addition, treated tumors showed significant dose-dependent decrease in mitotic activity index by 36.5% and 51% in comparison with the control group. In the chemoprevention study using rats, R. coriaria at a higher dose significantly reduced the tumor incidence by 20% and in lower dose non-significantly reduced tumor frequency by 29% when compared to controls. Evaluations of the mechanism of oncostatic action using valid clinical markers demonstrated several positive alterations in rat tumor cells after the treatment with R. coriaria. In this regard, histopathological analysis of treated tumor specimens showed robust dose-dependent decrease in the ratio of high-/low-grade carcinomas by 66% and 73% compared to controls. In treated rat carcinomas, we found significant caspase-3, Bax, and Bax/Bcl-2 expression increases; on the other side, a significant down-regulation of Bcl-2, Ki67, CD24, ALDH1, and EpCam expressions and MDA levels. When compared to control specimens, evaluation of epigenetic alterations in rat tumor cells in vivo showed significant dose-dependent decrease in lysine methylation status of H3K4m3 and H3K9m3 and dose-dependent increase in lysine acetylation in H4K16ac levels (H4K20m3 was not changed) in treated groups. However, only in lower dose of sumac were significant decreases in the expression of oncogenic miR210 and increase of tumor-suppressive miR145 (miR21, miR22, and miR155 were not changed) observed. Finally, only in lower sumac dose, significant decreases in methylation status of three out of five gene promoters-ATM, PTEN, and TIMP3 (PITX2 and RASSF1 promoters were not changed). In vitro evaluations using methanolic extract of R. coriaria showed significant anticancer efficacy in MCF-7 and MDA-MB-231 cells (using Resazurin, cell cycle, annexin V/PI, caspase-3/7, Bcl-2, PARP, and mitochondrial membrane potential analyses). In conclusion, sumac demonstrated significant oncostatic activities in rodent models of breast carcinoma that were validated by mechanistic studies in vivo and in vitro.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a fytogenní protinádorové látky $x farmakologie $7 D000972
- 650 _2
- $a apoptóza $7 D017209
- 650 _2
- $a nádorové biomarkery $x genetika $x metabolismus $7 D014408
- 650 _2
- $a nádory prsu $x farmakoterapie $x metabolismus $x patologie $7 D001943
- 650 _2
- $a buněčný cyklus $7 D002453
- 650 _2
- $a proliferace buněk $7 D049109
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u nádorů $x účinky léků $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední BALB C $7 D008807
- 650 _2
- $a myši nahé $7 D008819
- 650 _2
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a rostlinné extrakty $x farmakologie $7 D010936
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 650 _2
- $a Rhus $x chemie $7 D029045
- 650 _2
- $a nádorové buňky kultivované $7 D014407
- 650 _2
- $a xenogenní modely - testy protinádorové aktivity $7 D023041
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kello, Martin $u Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University, 040 11 Košice, Slovakia
- 700 1_
- $a Kajo, Karol $u Department of Pathology, St. Elisabeth Oncology Institute, 812 50 Bratislava, Slovakia $u Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia
- 700 1_
- $a Samec, Marek $u Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
- 700 1_
- $a Liskova, Alena $u Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
- 700 1_
- $a Jasek, Karin $u Division of Oncology, Biomedical Center Martin, Comenius University in Bratislava, Jessenius Faculty of Medicine, 036 01 Martin, Slovakia
- 700 1_
- $a Koklesova, Lenka $u Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
- 700 1_
- $a Kuruc, Tomas $u Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University, 040 11 Košice, Slovakia
- 700 1_
- $a Adamkov, Marian $u Department of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
- 700 1_
- $a Smejkal, Karel $u Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, 612 42 Brno, Czech Republic
- 700 1_
- $a Svajdlenka, Emil $u Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, 612 42 Brno, Czech Republic
- 700 1_
- $a Solar, Peter $u Department of Medical Biology, Faculty of Medicine, P. J. Šafárik University, 040 11 Kosice, Slovakia
- 700 1_
- $a Pec, Martin $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
- 700 1_
- $a Büsselberg, Dietrich $u Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, 24144 Doha, Qatar
- 700 1_
- $a Sadlonova, Vladimira $u Department of Microbiology and Immunology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
- 700 1_
- $a Mojzis, Jan $u Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University, 040 11 Košice, Slovakia
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 1 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33375383 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133010 $b ABA008
- 999 __
- $a ok $b bmc $g 1715140 $s 1146832
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 22 $c 1 $e 20201226 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a VEGA 1/0136/19; VEGA 1/0653/19; and 1/0753/17 $p Scientific Grant Agency of the Ministry of Education of the Slovak Republic
- GRA __
- $a APVV-16-0021 and APVV-16-0446 $p Slovak Research and Development Agency
- GRA __
- $a ITMS2014+: 313011V455 $p Open scientific community for modern interdisciplinary research in medicine (OPENMED)
- GRA __
- $a NPRP 11S-1214-170101 $p National Priorities Research Program grant (NPRP 11S-1214-170101; awarded to Professor Dr. Dietrich Büsselberg, June 2019-Current) from the Qatar National Research Fund (QNRF, a member of Qatar Foundation).
- LZP __
- $a Pubmed-20211013